Akebia Therapeutics, Inc. (AKBA), a leading biopharmaceutical company, is located in Cambridge, Massachusetts. It is dedicated to targeting and addressing the unmet medical needs of patients with kidney diseases. Established in 2007, the company leverages innovative scientific understanding with professional medical expertise to deliver high impact, unique therapeutic solutions.
With a committed stronghold in the renal drug market, Akebia Therapeutics has substantially contributed to the medical community. It is publicly traded on the Nasdaq stock market under the symbol AKBA. The company's commitment to scientific excellence and its dedication to corporate ethics make it a dynamic player in the biopharmaceutical landscape.
The primary focus of Akebia Therapeutics is renal diseases, specifically chronic kidney disease (CKD). CKD is a progressive ailment with increasingly limited treatment options. Akebia Therapeutics' primary product, Vadadustat – an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) - is currently in Phase 3 development as a potential treatment for anemia due to CKD.
Alongside Vadadustat, Akebia is also actively pursuing other innovative therapies for additional aspects of CKD. Its robust and diverse development strategy ensures the company’s sustainability and growth while pushing boundaries in renal disease solutions.
True to its vision, Akebia Therapeutics is recognized for its patient-centric approach. The company is highly committed to welfare and comfort of those suffering from CKD, striving to provide impactful medicines that allow patients to live improved lives. The company resonates with the belief that every patient deserves treatment options that are both accessible and affordable.
Moreover, another core component of the company’s vision is an emphasis on collaboration. Through partnerships with other biopharmaceutical companies, Akebia aims to maximize its therapeutic offerings and reach a wider demographic of patients. Collaboration also allows the company to maintain a sustainable core business and drive drug discovery and development.
Akebia Therapeutics, Inc. manages its business in compliance with U.S. regulations and lays high importance on ethical responsibility in research and development, clinical trials, and product marketing.
Despite navigating through a complex and competitive industry, Akebia Therapeutics is distinguished by its commitment towards patient wellness, its forward-thinking approach to innovation, and its resilience in the face of medical challenges. The company is consistently seeking to improve therapeutic options and patient outcomes, advancing their mission to make a powerful and lasting impact on the world of renal therapies.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
State Street Corp significantly reduced its stake in Akebia Therapeutics (NASDAQ:AKBA) by 53.6% in the second quarter, selling over 6.2 million shares. Despite this, other institutional investors have either increased or initiated positions in the biopharmaceutical company. Akebia Therapeutics reported better-than-expected Q2 earnings and revenue, with its lead product Vafseo approved for anemia associated with chronic kidney disease in dialysis patients.
Akebia Therapeutics has dosed the first patient in its Phase 2 basket trial for ebribafusp, an investigational treatment for rare complement-mediated kidney diseases like IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Ebribafusp is designed to specifically inhibit complement activation in kidney tissues without affecting the systemic complement system, aiming to offer a long-term treatment option with reduced infection risk. Initial data from the open-label trial, which will enroll up to 30 patients, is anticipated in 2027.
Akebia Therapeutics (NASDAQ:AKBA) has received an average "Hold" recommendation from seven brokerages, with an average 12-month price target of $3.90. The stock recently opened at $0.95, near its 12-month low, and institutional investors hold 33.92% of the shares. The company reported better-than-expected quarterly earnings and revenue, but a CFO recently sold shares to cover tax obligations.
Wall Street Zen has upgraded Akebia Therapeutics (NASDAQ:AKBA) from a "sell" to a "hold" rating. This aligns with MarketBeat's consensus "Hold" rating, which includes four Buy, two Hold, and one Sell rating, with an average price target of $3.90. The company's stock is currently trading near its 52-week low, despite beating analyst expectations for its last quarterly revenue and adjusted EPS.
Westpark Capital initiated coverage on Akebia Therapeutics (NASDAQ:AKBA) with a "buy" rating and a $4.50 price target, suggesting a significant upside. Despite this, the consensus rating from analysts remains "Hold" with an average target price of $3.90, reflecting mixed sentiment. The biopharmaceutical company recently reported better-than-expected quarterly revenue of $49.13 million and a narrower loss of $0.02 per share.